Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod induction in ulcerative colitis
NCT03996369Phase 3Completed
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 41
01
Overview
Phase 3, randomised, double-blind trial in ulcerative colitis (UC) comparing Etrasimod 2 mg with Placebo (2 arms). Primary endpoint: Percentage of Participants Achieving Clinical Remission at 12 weeks. Started Sep 2020; status: completed.
02
Drugs
etrasimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03996369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03996369.